title: Redesign of substrate specificity and identification of the aminoglycoside binding residues of Eis from Mycobacterium tuberculosis.
abstract: The upsurge in drug-resistant tuberculosis (TB) is an emerging global problem. The increased expression of the enhanced intracellular survival (Eis) protein is responsible for the clinical resistance to aminoglycoside (AG) antibiotics of Mycobacterium tuberculosis . Eis from M. tuberculosis (Eis_Mtb) and M. smegmatis (Eis_Msm) function as acetyltransferases capable of acetylating multiple amines of many AGs; however, these Eis homologues differ in AG substrate preference and in the number of acetylated amine groups per AG. The AG binding cavity of Eis_Mtb is divided into two narrow channels, whereas Eis_Msm contains one large cavity. Five bulky residues lining one of the AG binding channels of Eis_Mtb, His119, Ile268, Trp289, Gln291, and Glu401, have significantly smaller counterparts in Eis_Msm, Thr119, Gly266, Ala287, Ala289, and Gly401, respectively. To identify the residue(s) responsible for AG binding in Eis_Mtb and for the functional differences from Eis_Msm, we have generated single, double, triple, quadruple, and quintuple mutants of these residues in Eis_Mtb by mutating them into their Eis_Msm counterparts, and we tested their acetylation activity with three structurally diverse AGs: kanamycin A (KAN), paromomyin (PAR), and apramycin (APR). We show that penultimate C-terminal residue Glu401 plays a critical role in the overall activity of Eis_Mtb. We also demonstrate that the identities of residues Ile268, Trp289, and Gln291 (in Eis_Mtb nomenclature) dictate the differences between the acetylation efficiencies of Eis_Mtb and Eis_Msm for KAN and PAR. Finally, we show that the mutation of Trp289 in Eis_Mtb into Ala plays a role in APR acetylation.
authors.affiliation: Life Sciences Institute, 210 Washtenaw Avenue, University of Michigan, Ann Arbor, Michigan 48109-2216, United States.
authors.forename: Benjamin C
authors.initials: BC
authors.lastname: Jennings
authors.forename: Kristin J
authors.initials: KJ
authors.lastname: Labby
authors.forename: Keith D
authors.initials: KD
authors.lastname: Green
authors.forename: Sylvie
authors.initials: S
authors.lastname: Garneau-Tsodikova
mesh_terms: D000107:Acetylation; D000123:Acetyltransferases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D000595:Amino Acid Sequence; D019943:Amino Acid Substitution; D000617:Aminoglycosides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D000904:Antibiotics, Antitubercular / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D001426:Bacterial Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D001665:Binding Sites; D024901:Drug Resistance, Multiple, Bacterial; D007612:Kanamycin / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D008968:Molecular Conformation; D050505:Mutant Proteins / Q000737:chemistry / Q000378:metabolism; D020102:Mycobacterium smegmatis / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D009328:Nebramycin / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D010303:Paromomycin / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D016415:Sequence Alignment; D013379:Substrate Specificity
chemical_list: D000617:Aminoglycosides; D000904:Antibiotics, Antitubercular; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D050505:Mutant Proteins; D011994:Recombinant Proteins; D009328:Nebramycin; C011666:apramycin; D007612:Kanamycin; D010303:Paromomycin; D000123:Acetyltransferases; C430563:Eis protein, Mycobacterium tuberculosis